Yves Bikorimana: What Every Lab and Clinician Should Know on Pseudothrombocytopenia
Yves Bikorimana, CEO at MedData-Rwanda and Lab Scientist at The University Teaching Hospital of Kigali-Chuk, shared a post on LinkedIn.
“Pseudothrombocytopenia (PTCP): What Every Lab and Clinician Should Know
Pseudothrombocytopenia is a laboratory artifact where platelet counts appear falsely low on automated analyzers, despite the patient having a normal platelet count in vivo. Importantly, it is not a true clinical thrombocytopenia and does not increase bleeding risk.
Why does it happen?
The most common cause is EDTA-dependent platelet clumping. In some individuals, EDTA (the anticoagulant used in routine CBC tubes) exposes platelet surface antigens, leading to antibody-mediated platelet aggregation. Automated analyzers then misinterpret these clumps as leukocytes or exclude them entirely, resulting in a falsely low platelet count.
Key Laboratory Features
- Low platelet count on automated CBC
- Platelet clumps visible on peripheral blood smear
- Normal platelet count when blood is collected in:
- Sodium citrate
- Heparin
- Magnesium sulfate (rarely used but effective)
Clinical Significance
- Patients are usually asymptomatic
- No bleeding manifestations
- Can be mistaken for serious conditions like:
- Immune thrombocytopenic purpura (ITP)
- Bone marrow disorders
- Drug-induced thrombocytopenia
Why recognition matters
Failure to identify PTCP can lead to:
- Unnecessary platelet transfusions
- Inappropriate treatments (e.g., steroids, IVIG)
- Delays in surgeries or invasive procedures
- Patient anxiety and misdiagnosis
Best Practice Approach
- Always review the peripheral smear when thrombocytopenia is detected
- Repeat platelet count using an alternative anticoagulant
- Correlate laboratory findings with clinical presentation
Take-home message
Pseudothrombocytopenia highlights the importance of laboratory-clinical correlation and the continued value of manual smear examination in modern diagnostics.”
Find the latest updates on Hemostasis Today.
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:49Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
-
Jul 13, 2026, 10:25Flora Peyvandi: A Practical Approach to ALT Elevation After Gene Therapy at ISTH 2026
-
Jul 13, 2026, 10:02Jessica Garcia: Where Science and Community Come Together at ISTH 2026
-
Jul 13, 2026, 09:46Fabrice Cognasse: Is There Such a Thing as the Perfect Platelet Product?
-
Jul 13, 2026, 09:42Cancer-Associated Arterial Thromboembolism: Redefining the Thrombotic Burden in Oncology
-
Jul 13, 2026, 05:59Connecting and Collaborating at ISTH 2026 – NNHF
-
Jul 13, 2026, 05:58Lara Monica: Back at ISTH – Looking Forward to Science and Reconnections!
-
Jul 13, 2026, 05:57Barbara Adams Krolak: Exciting Updates From the ISTH 2026 Regulatory Session